MEDINDIA
English
हिन्दी
Español
français
中文
Email
4-Hydroxybutyric Acid
The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lithium.
Aceclofenac
The serum concentration of Lithium can be increased when it is combined with Aceclofenac.
Acemetacin
The serum concentration of Lithium can be increased when it is combined with Acemetacin.
Acepromazine
Lithium may increase the neurotoxic activities of Acepromazine.
Aceprometazine
Lithium may increase the neurotoxic activities of Aceprometazine.
Acetazolamide
The serum concentration of Lithium can be decreased when it is combined with Acetazolamide.
Acetophenazine
Lithium may increase the neurotoxic activities of Acetophenazine.
Acetyl salicylate
The serum concentration of Lithium can be increased when it is combined with Acetylsalicylic acid.
Adapalene
The serum concentration of Lithium can be increased when it is combined with Adapalene.
Alfaxalone
The risk or severity of adverse effects can be increased when Lithium is combined with Alfaxalone.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Lithium.
Alminoprofen
The serum concentration of Lithium can be increased when it is combined with Alminoprofen.
Almotriptan
The risk or severity of adverse effects can be increased when Almotriptan is combined with Lithium.
Alphaprodine
The risk or severity of adverse effects can be increased when Lithium is combined with Alphaprodine.
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Lithium.
AMBROXOL ACEFYLLINATE
The serum concentration of Lithium can be decreased when it is combined with Ambroxol acefyllinate.
Ambroxol-Theophylline-7-Acetate
The serum concentration of Lithium can be decreased when it is combined with Ambroxol acefyllinate.
Amineptin
Lithium may increase the neurotoxic activities of Amineptine.
Aminophylline
The serum concentration of Lithium can be decreased when it is combined with Aminophylline.
Amiodarone
Lithium may increase the QTc-prolonging activities of Amiodarone.
Amisulpride
Lithium may increase the antipsychotic activities of Amisulpride.
Amitriptyline
Lithium may increase the neurotoxic activities of Amitriptyline.
Amobarbital
The risk or severity of adverse effects can be increased when Amobarbital is combined with Lithium.
Amoxapine
Lithium may increase the neurotoxic activities of Amoxapine.
Amphetamine
The risk or severity of adverse effects can be increased when Amphetamine is combined with Lithium.
Anagrelide
Lithium may increase the QTc-prolonging activities of Anagrelide.
Antipyrine
The serum concentration of Lithium can be increased when it is combined with Antipyrine.
Apazone
The serum concentration of Lithium can be increased when it is combined with Azapropazone.
Apremilast
The serum concentration of Lithium can be increased when it is combined with Apremilast.
Aripiprazole
Lithium may increase the neurotoxic activities of Aripiprazole.
Arsenic Trioxide
Lithium may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Lithium may increase the QTc-prolonging activities of Artemether.
Articaine
The risk or severity of adverse effects can be increased when Lithium is combined with Articaine.
Asenapine
Lithium may increase the neurotoxic activities of Asenapine.
Aspirin
The serum concentration of Lithium can be increased when it is combined with Acetylsalicylic acid.
Atracurium
Lithium may increase the neuromuscular blocking activities of Atracurium.
Atracurium Besylate
Lithium may increase the neuromuscular blocking activities of Atracurium besylate.
Azelastine
Lithium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Azilsartan
The serum concentration of Lithium can be increased when it is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The serum concentration of Lithium can be increased when it is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The serum concentration of Lithium can be increased when it is combined with Azilsartan medoxomil.
Azithromycin
Lithium may increase the QTc-prolonging activities of Azithromycin.
Azosemide
The serum concentration of Lithium can be decreased when it is combined with Azosemide.
Baclofen
The risk or severity of adverse effects can be increased when Baclofen is combined with Lithium.
Balsalazide
The serum concentration of Lithium can be increased when it is combined with Balsalazide.
Barbital
The risk or severity of adverse effects can be increased when Lithium is combined with Barbital.
Bedaquiline
Lithium may increase the QTc-prolonging activities of Bedaquiline.
Benazepril
The serum concentration of Lithium can be increased when it is combined with Benazepril.
Bendroflumethiazide
Bendroflumethiazide may decrease the excretion rate of Lithium which could result in a higher serum level.
Benoxinate
The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lithium.
Benperidol
Lithium may increase the neurotoxic activities of Benperidol.
Benzocaine
The risk or severity of adverse effects can be increased when Benzocaine is combined with Lithium.
Benzphetamine
Lithium may decrease the stimulatory activities of Benzphetamine.
Benzydamine
The serum concentration of Lithium can be increased when it is combined with Benzydamine.
Benzyl Alcohol
The risk or severity of adverse effects can be increased when Lithium is combined with Benzyl alcohol.
Brexpiprazole
Lithium may increase the neurotoxic activities of Brexpiprazole.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lithium.
Brinzolamide
The serum concentration of Lithium can be decreased when it is combined with Brinzolamide.
Bromazepam
The risk or severity of adverse effects can be increased when Bromazepam is combined with Lithium.
Bromfenac
The serum concentration of Lithium can be increased when it is combined with Bromfenac.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lithium.
Bromperidol
Lithium may increase the neurotoxic activities of Bromperidol.
Brompheniramine
The risk or severity of adverse effects can be increased when Brompheniramine is combined with Lithium.
Brotizolam
The risk or severity of adverse effects can be increased when Lithium is combined with Brotizolam.
Bufexamac
The serum concentration of Lithium can be increased when it is combined with Bufexamac.
Bumetanide
The serum concentration of Lithium can be decreased when it is combined with Bumetanide.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lithium.
Buprenorphine
Lithium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Buspirone
The risk or severity of adverse effects can be increased when Buspirone is combined with Lithium.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Lithium.
Butalbital
The risk or severity of adverse effects can be increased when Butalbital is combined with Lithium.
Butamben
The risk or severity of adverse effects can be increased when Lithium is combined with Butamben.
Butobarbital
The risk or severity of adverse effects can be increased when Butethal is combined with Lithium.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Lithium.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Lithium.
Caffeine
The serum concentration of Lithium can be decreased when it is combined with Caffeine.
Candesartan
The serum concentration of Lithium can be increased when it is combined with Candesartan.
Candesartan Cilexetil
The serum concentration of Lithium can be increased when it is combined with Candesartan cilexetil.
Captopril
The serum concentration of Lithium can be increased when it is combined with Captopril.
Carbamazepine
The risk or severity of adverse effects can be increased when Carbamazepine is combined with Lithium.
Carbinoxamine
The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Lithium.
Cariprazine
Lithium may increase the neurotoxic activities of Cariprazine.
Carisoprodol
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Lithium.
Carprofen
The serum concentration of Lithium can be increased when it is combined with Carprofen.
Celecoxib
The serum concentration of Lithium can be increased when it is combined with Celecoxib.
Ceritinib
Lithium may increase the QTc-prolonging activities of Ceritinib.
Cetirizine
The risk or severity of adverse effects can be increased when Cetirizine is combined with Lithium.
Chloral Hydrate
The risk or severity of adverse effects can be increased when Lithium is combined with Chloral hydrate.
Chlordiazepoxide
The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lithium.
Chlormethiazole
The risk or severity of adverse effects can be increased when Lithium is combined with clomethiazole.
Chlormezanone
The risk or severity of adverse effects can be increased when Chlormezanone is combined with Lithium.
Chloroprocaine
The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lithium.
Chloroquine
The serum concentration of Lithium can be increased when it is combined with Chloroquine.
Chlorothiazide
Chlorothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.
Chlorpheniramine
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lithium.
CHLORPHENIRAMINE POLISTIREX
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Lithium.
Chlorpromazine
Lithium may increase the neurotoxic activities of Chlorpromazine.
Chlorprothixene
Lithium may increase the neurotoxic activities of Chlorprothixene.
Chlorthalidone
Chlorthalidone may decrease the excretion rate of Lithium which could result in a higher serum level.
Chlorzoxazone
The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Lithium.
Choline Magnesium Trisalicyclate
The serum concentration of Lithium can be increased when it is combined with Choline magnesium trisalicylate.
Cilazapril
The serum concentration of Lithium can be increased when it is combined with Cilazapril.
Ciprofloxacin
Lithium may increase the QTc-prolonging activities of Ciprofloxacin.
Cisapride
Lithium may increase the QTc-prolonging activities of Cisapride.
Cisatracurium
Lithium may increase the neuromuscular blocking activities of Cisatracurium besylate.
Citalopram
Lithium may increase the serotonergic activities of Citalopram.
Clarithromycin
Lithium may increase the QTc-prolonging activities of Clarithromycin.
Clemastine
The risk or severity of adverse effects can be increased when Clemastine is combined with Lithium.
Clidinium
The risk or severity of adverse effects can be increased when Clidinium is combined with Lithium.
Clidinium bromide
The risk or severity of adverse effects can be increased when Clidinium is combined with Lithium.
Clobazam
The risk or severity of adverse effects can be increased when Clobazam is combined with Lithium.
Clomipramine
Lithium may increase the neurotoxic activities of Clomipramine.
Clonazepam
The risk or severity of adverse effects can be increased when Clonazepam is combined with Lithium.
Clonidine
The risk or severity of adverse effects can be increased when Clonidine is combined with Lithium.
Clonixin
The serum concentration of Lithium can be increased when it is combined with Clonixin.
Clorazepate
The risk or severity of adverse effects can be increased when Clorazepate is combined with Lithium.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Clorazepate is combined with Lithium.
Clozapine
Lithium may increase the neurotoxic activities of Clozapine.
Cocaine
The risk or severity of adverse effects can be increased when Cocaine is combined with Lithium.
Codeine
The risk or severity of adverse effects can be increased when Codeine is combined with Lithium.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Codeine is combined with Lithium.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Codeine is combined with Lithium.
Crizotinib
Lithium may increase the QTc-prolonging activities of Crizotinib.
Curcumin
The serum concentration of Lithium can be increased when it is combined with Curcumin.
Cyamemazine
Lithium may increase the neurotoxic activities of Cyamemazine.
Cyclizine
The risk or severity of adverse effects can be increased when Cyclizine is combined with Lithium.
Cyclobenzaprine
Lithium may increase the neurotoxic activities of Cyclobenzaprine.
Cyclopenthiazide
Cyclopenthiazide may decrease the excretion rate of Lithium which could result in a higher serum level.
Cyproheptadine
The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Lithium.
Dantrolene
The risk or severity of adverse effects can be increased when Dantrolene is combined with Lithium.
Dapiprazole
Lithium may increase the neurotoxic activities of Dapiprazole.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Lithium.
Desipramine
Lithium may increase the neurotoxic activities of Desipramine.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Lithium.
Desmopressin
The therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium.
Desvenlafaxine
Lithium may increase the serotonergic activities of Desvenlafaxine.
Deutetrabenazine
The risk or severity of adverse effects can be increased when Lithium is combined with Deutetrabenazine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lithium.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lithium.
Dextroamphetamine
Lithium may decrease the stimulatory activities of Dextroamphetamine.
Dextromethorphan
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lithium.
Dextromoramide
The risk or severity of adverse effects can be increased when Lithium is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Dezocine is combined with Lithium.
Diazepam
The risk or severity of adverse effects can be increased when Diazepam is combined with Lithium.
Dibucaine
The risk or severity of adverse effects can be increased when Cinchocaine is combined with Lithium.
Dichlorphenamide
The serum concentration of Lithium can be decreased when it is combined with Diclofenamide.
Diclofenac
The serum concentration of Lithium can be increased when it is combined with Diclofenac.
Diethylpropion
Lithium may decrease the stimulatory activities of Diethylpropion.
Difenoxin
The risk or severity of adverse effects can be increased when Difenoxin is combined with Lithium.
Diflunisal
The serum concentration of Lithium can be increased when it is combined with Diflunisal.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lithium.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lithium.
Diltiazem
Diltiazem may increase the neurotoxic activities of Lithium.
Dimenhydrinate
The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lithium.
Diphenhydramine
The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lithium.
Diphenoxylate
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lithium.
Dipyrone
The serum concentration of Lithium can be increased when it is combined with Metamizole.
Disopyramide
Lithium may increase the QTc-prolonging activities of Disopyramide.
Dofetilide
Lithium may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Lithium may increase the QTc-prolonging activities of Dolasetron.
Domperidone
Lithium may increase the QTc-prolonging activities of Domperidone.
Dorzolamide
The serum concentration of Lithium can be decreased when it is combined with Dorzolamide.
Dothiepin
Lithium may increase the neurotoxic activities of Dosulepin.
Doxacurium Chloride
Lithium may increase the neuromuscular blocking activities of Doxacurium chloride.
Doxepin
Lithium may increase the neurotoxic activities of Doxepin.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lithium.
Dronedarone
Lithium may increase the QTc-prolonging activities of Dronedarone.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Lithium.
Droxicam
The serum concentration of Lithium can be increased when it is combined with Droxicam.
Duloxetine
Lithium may increase the serotonergic activities of Duloxetine.
Dyclonine
The risk or severity of adverse effects can be increased when Dyclonine is combined with Lithium.
Dyphylline
The serum concentration of Lithium can be decreased when it is combined with Dyphylline.
Efavirenz
The risk or severity of adverse effects can be increased when Efavirenz is combined with Lithium.
Eletriptan
The risk or severity of adverse effects can be increased when Eletriptan is combined with Lithium.
Eliglustat
Lithium may increase the QTc-prolonging activities of Eliglustat.
Enalapril
The serum concentration of Lithium can be increased when it is combined with Enalapril.
Enalaprilat
The serum concentration of Lithium can be increased when it is combined with Enalaprilat.
Enalaprilat Anhydrous
The serum concentration of Lithium can be increased when it is combined with Enalaprilat.
Enflurane
The risk or severity of adverse effects can be increased when Enflurane is combined with Lithium.
Entacapone
The risk or severity of adverse effects can be increased when Entacapone is combined with Lithium.
Eplerenone
The serum concentration of Lithium can be increased when it is combined with Eplerenone.
Eprosartan
The serum concentration of Lithium can be increased when it is combined with Eprosartan.
ergoloid mesylates, USP
The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lithium.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Lithium.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Lithium.
Erythromycin
Lithium may increase the QTc-prolonging activities of Erythromycin.
Escitalopram
Lithium may increase the serotonergic activities of Escitalopram.
Estazolam
The risk or severity of adverse effects can be increased when Estazolam is combined with Lithium.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Lithium.
Etanercept
The serum concentration of Lithium can be increased when it is combined with Etanercept.
Ethacrynate
The serum concentration of Lithium can be decreased when it is combined with Etacrynic acid.
Ethacrynic Acid
The serum concentration of Lithium can be decreased when it is combined with Etacrynic acid.
Ethanol
Lithium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lithium.
Ethosuximide
The risk or severity of adverse effects can be increased when Ethosuximide is combined with Lithium.
Ethotoin
The risk or severity of adverse effects can be increased when Ethotoin is combined with Lithium.
Ethyl Chloride
The risk or severity of adverse effects can be increased when Lithium is combined with Ethyl chloride.
Ethyl Loflazepate
The risk or severity of adverse effects can be increased when Lithium is combined with Ethyl loflazepate.
Ethylmorphine
The risk or severity of adverse effects can be increased when Lithium is combined with Ethylmorphine.
Etidocaine
The risk or severity of adverse effects can be increased when Lithium is combined with Etidocaine.
Etifoxine
The risk or severity of adverse effects can be increased when Lithium is combined with Etifoxine.
Etodolac
The serum concentration of Lithium can be increased when it is combined with Etodolac.
Etofenamate
The serum concentration of Lithium can be increased when it is combined with Etofenamate.
Etomidate
The risk or severity of adverse effects can be increased when Etomidate is combined with Lithium.
Etoricoxib
The serum concentration of Lithium can be increased when it is combined with Etoricoxib.
Evening primrose oil
The serum concentration of Lithium can be increased when it is combined with Evening primrose oil.
Ezogabine
The risk or severity of adverse effects can be increased when Ezogabine is combined with Lithium.
Felbamate
The risk or severity of adverse effects can be increased when Felbamate is combined with Lithium.
Felbinac
The serum concentration of Lithium can be increased when it is combined with Felbinac.
Fenbufen
The serum concentration of Lithium can be increased when it is combined with Fenbufen.
Fenoprofen
The serum concentration of Lithium can be increased when it is combined with Fenoprofen.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Lithium.
Ferulic Acid
The serum concentration of Lithium can be increased when it is combined with Ferulic acid.
Fexofenadine
The risk or severity of adverse effects can be increased when Fexofenadine is combined with Lithium.
Flecainide
Lithium may increase the QTc-prolonging activities of Flecainide.
Flibanserin
The risk or severity of adverse effects can be increased when Flibanserin is combined with Lithium.
Floctafenine
The serum concentration of Lithium can be increased when it is combined with Floctafenine.
Flunarizine
The risk or severity of adverse effects can be increased when Flunarizine is combined with Lithium.
Flunitrazepam
The risk or severity of adverse effects can be increased when Lithium is combined with Flunitrazepam.
Fluoxetine
Lithium may increase the serotonergic activities of Fluoxetine.
Flupenthixol
Lithium may increase the neurotoxic activities of Flupentixol.
Fluphenazine
Lithium may increase the neurotoxic activities of Fluphenazine.
Flurazepam
The risk or severity of adverse effects can be increased when Flurazepam is combined with Lithium.
Flurbiprofen
The serum concentration of Lithium can be increased when it is combined with Flurbiprofen.
Fluspirilene
Lithium may increase the neurotoxic activities of Fluspirilene.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Lithium.
Fluvoxamine
Lithium may increase the serotonergic activities of Fluvoxamine.
Fosinopril
The serum concentration of Lithium can be increased when it is combined with Fosinopril.
Fosphenytoin
The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Lithium.
Fospropofol
The risk or severity of adverse effects can be increased when Lithium is combined with Fospropofol.
Frovatriptan
The risk or severity of adverse effects can be increased when Frovatriptan is combined with Lithium.
Furazolidone
The risk or severity of adverse effects can be increased when Furazolidone is combined with Lithium.
Furosemide
The serum concentration of Lithium can be decreased when it is combined with Furosemide.
Gabapentin
The risk or severity of adverse effects can be increased when Gabapentin is combined with Lithium.
Gabapentin Enacarbil
The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Lithium.
Gadobenate
Lithium may increase the QTc-prolonging activities of Gadobenic acid.
Gallamine Triethiodide
Lithium may increase the neuromuscular blocking activities of Gallamine Triethiodide.
Gemifloxacin
Lithium may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Lithium may increase the QTc-prolonging activities of Gemifloxacin.
Glutethimide
The risk or severity of adverse effects can be increased when Lithium is combined with Glutethimide.
Goserelin
Lithium may increase the QTc-prolonging activities of Goserelin.
Granisetron
Lithium may increase the QTc-prolonging activities of Granisetron.
Guanfacine
The risk or severity of adverse effects can be increased when Guanfacine is combined with Lithium.
Halazepam
The risk or severity of adverse effects can be increased when Halazepam is combined with Lithium.
Haloperidol
Lithium may increase the neurotoxic activities of Haloperidol.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Lithium.
Heroin
The risk or severity of adverse effects can be increased when Lithium is combined with Heroin.
Hexobarbital
The risk or severity of adverse effects can be increased when Hexobarbital is combined with Lithium.
Human calcitonin
The serum concentration of Lithium can be decreased when it is combined with Human calcitonin.
Hydrochlorothiazide
Hydrochlorothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.
Hydrocodone
Lithium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HYDROCODONE POLISTIREX
Lithium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroflumethiazide
Hydroflumethiazide may decrease the excretion rate of Lithium which could result in a higher serum level.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lithium.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lithium.
Ibuprofen
The serum concentration of Lithium can be increased when it is combined with Ibuprofen.
Ibutilide
Lithium may increase the QTc-prolonging activities of Ibutilide.
Icatibant
The serum concentration of Lithium can be increased when it is combined with Icatibant.
Iloperidone
Lithium may increase the neurotoxic activities of Iloperidone.
Imidapril
The serum concentration of Lithium can be increased when it is combined with Imidapril.
Imipramine
Lithium may increase the neurotoxic activities of Imipramine.
Indapamide
Indapamide may decrease the excretion rate of Lithium which could result in a higher serum level.
Indobufen
The serum concentration of Lithium can be increased when it is combined with Indobufen.
Indomethacin
The serum concentration of Lithium can be increased when it is combined with Indomethacin.
Iproniazid
The risk or severity of adverse effects can be increased when Iproniazid is combined with Lithium.
Irbesartan
The serum concentration of Lithium can be increased when it is combined with Irbesartan.
Isocarboxazid
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lithium.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Lithium.
Kebuzone
The serum concentration of Lithium can be increased when it is combined with Kebuzone.
Ketamine
The risk or severity of adverse effects can be increased when Ketamine is combined with Lithium.
Ketazolam
The risk or severity of adverse effects can be increased when Lithium is combined with Ketazolam.
Ketoprofen
The serum concentration of Lithium can be increased when it is combined with Ketoprofen.
Ketorolac
The serum concentration of Lithium can be increased when it is combined with Ketorolac.
Lamotrigine
The risk or severity of adverse effects can be increased when Lamotrigine is combined with Lithium.
Leflunomide
The serum concentration of Lithium can be increased when it is combined with Leflunomide.
Lenvatinib
Lithium may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Lithium may increase the QTc-prolonging activities of Lenvatinib.
Leuprolide
Lithium may increase the QTc-prolonging activities of Leuprolide.
Levetiracetam
The risk or severity of adverse effects can be increased when Levetiracetam is combined with Lithium.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Lithium.
Levocabastine
The risk or severity of adverse effects can be increased when Lithium is combined with Levocabastine.
Levocetirizine
The risk or severity of adverse effects can be increased when Levocetirizine is combined with Lithium.
Levodopa
The risk or severity of adverse effects can be increased when Levodopa is combined with Lithium.
Levofloxacin
Lithium may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Lithium may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl
The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lithium.
Levomilnacipran
Lithium may increase the serotonergic activities of Levomilnacipran.
Levorphanol
The risk or severity of adverse effects can be increased when Levorphanol is combined with Lithium.
Lidocaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Lithium.
Limonene, (+)-
The serum concentration of Lithium can be increased when it is combined with (4R)-limonene.
Linezolid
The risk or severity of adverse effects can be increased when Linezolid is combined with Lithium.
Lisdexamfetamine
Lithium may decrease the stimulatory activities of Lisdexamfetamine.
Lisdexamfetamine Dimesylate
Lithium may decrease the stimulatory activities of Lisdexamfetamine.
Lisinopril
The serum concentration of Lithium can be increased when it is combined with Lisinopril.
Lisinopril Anhydrous
The serum concentration of Lithium can be increased when it is combined with Lisinopril.
Lopinavir
Lithium may increase the QTc-prolonging activities of Lopinavir.
Loratadine
The risk or severity of adverse effects can be increased when Loratadine is combined with Lithium.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lithium.
Lorcaserin
The risk or severity of adverse effects can be increased when Lithium is combined with Lorcaserin.
Lormetazepam
The risk or severity of adverse effects can be increased when Lithium is combined with Lormetazepam.
Lornoxicam
The serum concentration of Lithium can be increased when it is combined with Lornoxicam.
Losartan
The serum concentration of Lithium can be increased when it is combined with Losartan.
Loxapine
Lithium may increase the neurotoxic activities of Loxapine.
Loxoprofen
The serum concentration of Lithium can be increased when it is combined with Loxoprofen.
Lumefantrine
Lithium may increase the QTc-prolonging activities of Lumefantrine.
Lurasidone
Lithium may increase the neurotoxic activities of Lurasidone.
Magnesium Salicylate
The serum concentration of Lithium can be increased when it is combined with Magnesium salicylate.
Magnesium Sulfate
The therapeutic efficacy of Lithium can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Lithium can be increased when used in combination with Magnesium sulfate.
Maprotiline
The risk or severity of adverse effects can be increased when Maprotiline is combined with Lithium.
Masoprocol
The serum concentration of Lithium can be increased when it is combined with Masoprocol.
Meclizine
The risk or severity of adverse effects can be increased when Meclizine is combined with Lithium.
Meclofenamate
The serum concentration of Lithium can be increased when it is combined with Meclofenamic acid.
Meclofenamic Acid
The serum concentration of Lithium can be increased when it is combined with Meclofenamic acid.
Mefenamic Acid
The serum concentration of Lithium can be increased when it is combined with Mefenamic acid.
Melatonin
The risk or severity of adverse effects can be increased when Melatonin is combined with Lithium.
Meloxicam
The serum concentration of Lithium can be increased when it is combined with Meloxicam.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Lithium.
Mephentermine
Lithium may decrease the stimulatory activities of Mephentermine.
Mephobarbital
The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lithium.
Mepivacaine
The risk or severity of adverse effects can be increased when Mepivacaine is combined with Lithium.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Lithium.
Mequitazine
Lithium may increase the arrhythmogenic activities of Mequitazine.
Mesalamine
The serum concentration of Lithium can be increased when it is combined with Mesalazine.
Mesoridazine
Lithium may increase the neurotoxic activities of Mesoridazine.
Metaxalone
The risk or severity of adverse effects can be increased when Metaxalone is combined with Lithium.
Methadone
The risk or severity of adverse effects can be increased when Methadone is combined with Lithium.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Lithium is combined with Methadyl Acetate.
Methamphetamine
Lithium may decrease the stimulatory activities of Methamphetamine.
Methapyrilene
The risk or severity of adverse effects can be increased when Lithium is combined with Methapyrilene.
Methaqualone
The risk or severity of adverse effects can be increased when Lithium is combined with Methaqualone.
Methazolamide
The serum concentration of Lithium can be decreased when it is combined with Methazolamide.
Methocarbamol
The risk or severity of adverse effects can be increased when Methocarbamol is combined with Lithium.
Methohexital
The risk or severity of adverse effects can be increased when Methohexital is combined with Lithium.
Methotrimeprazine
Lithium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxyflurane
The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lithium.
Methsuximide
The risk or severity of adverse effects can be increased when Methsuximide is combined with Lithium.
Methyclothiazide
Methyclothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.
Methyldopa
The risk or severity of adverse effects can be increased when Methyldopa is combined with Lithium.
METHYLDOPA ANHYDROUS
The risk or severity of adverse effects can be increased when Methyldopa is combined with Lithium.
Methylene blue
The risk or severity of adverse effects can be increased when Methylene blue is combined with Lithium.
Methylphenidate
The risk or severity of adverse effects can be increased when Lithium is combined with Methylphenidate.
Metoclopramide
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Lithium.
Metocurine
Lithium may increase the neuromuscular blocking activities of Metocurine.
Metocurine iodide
Lithium may increase the neuromuscular blocking activities of Metocurine Iodide.
Metolazone
Metolazone may decrease the excretion rate of Lithium which could result in a higher serum level.
Metylperon
Lithium may increase the neurotoxic activities of Melperone.
Metyrosine
Lithium may increase the sedative activities of Metyrosine.
Midazolam
The risk or severity of adverse effects can be increased when Midazolam is combined with Lithium.
Mifepristone
Mifepristone may increase the QTc-prolonging activities of Lithium.
Milnacipran
Lithium may increase the serotonergic activities of Milnacipran.
Minaprine
The risk or severity of adverse effects can be increased when Minaprine is combined with Lithium.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lithium.
Mirtazapine
Lithium may increase the neurotoxic activities of Mirtazapine.
Mivacurium
Lithium may increase the neuromuscular blocking activities of Mivacurium.
Moclobemide
The risk or severity of adverse effects can be increased when Moclobemide is combined with Lithium.
Moexipril
The serum concentration of Lithium can be increased when it is combined with Moexipril.
Molindone
Lithium may increase the neurotoxic activities of Molindone.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Lithium.
Moxifloxacin
Lithium may increase the QTc-prolonging activities of Moxifloxacin.
MYCOPHENOLATE
The serum concentration of Lithium can be increased when it is combined with Mycophenolic acid.
Mycophenolate Mofetil
The serum concentration of Lithium can be increased when it is combined with Mycophenolate mofetil.
Mycophenolic Acid
The serum concentration of Lithium can be increased when it is combined with Mycophenolic acid.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lithium.
Nabumetone
The serum concentration of Lithium can be increased when it is combined with Nabumetone.
Naftifine
The serum concentration of Lithium can be increased when it is combined with Naftifine.
Nalbuphine
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Lithium.
Naproxen
The serum concentration of Lithium can be increased when it is combined with Naproxen.
Naratriptan
The risk or severity of adverse effects can be increased when Naratriptan is combined with Lithium.
Nefazodone
Lithium may increase the serotonergic activities of Nefazodone.
Nepafenac
The serum concentration of Lithium can be increased when it is combined with Nepafenac.
Nialamide
The risk or severity of adverse effects can be increased when Nialamide is combined with Lithium.
Niflumic Acid
The serum concentration of Lithium can be increased when it is combined with Niflumic Acid.
Nilotinib
Lithium may increase the QTc-prolonging activities of Nilotinib.
Nimesulide
The serum concentration of Lithium can be increased when it is combined with Nimesulide.
Nitrazepam
The risk or severity of adverse effects can be increased when Nitrazepam is combined with Lithium.
Nitrous Oxide
The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lithium.
Norflurane
The risk or severity of adverse effects can be increased when Lithium is combined with Norflurane.
Normethadone
The risk or severity of adverse effects can be increased when Lithium is combined with Normethadone.
Nortriptyline
Lithium may increase the neurotoxic activities of Nortriptyline.
Oenothera biennis seed extract
The serum concentration of Lithium can be increased when it is combined with Evening primrose oil.
Ofloxacin
Lithium may increase the QTc-prolonging activities of Ofloxacin.
Olanzapine
Lithium may increase the neurotoxic activities of Olanzapine.
Olmesartan
The serum concentration of Lithium can be increased when it is combined with Olmesartan.
Olopatadine
The serum concentration of Lithium can be increased when it is combined with Olopatadine.
Olsalazine
The serum concentration of Lithium can be increased when it is combined with Olsalazine.
Ondansetron
Lithium may increase the neurotoxic activities of Ondansetron.
Opipramol
Lithium may increase the neurotoxic activities of Opipramol.
Opium
The risk or severity of adverse effects can be increased when Lithium is combined with Opium.
Orphenadrine
Lithium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Oxaprozin
The serum concentration of Lithium can be increased when it is combined with Oxaprozin.
Oxazepam
The risk or severity of adverse effects can be increased when Oxazepam is combined with Lithium.
Oxprenolol
The risk or severity of adverse effects can be increased when Lithium is combined with Oxprenolol.
Oxycodone
The risk or severity of adverse effects can be increased when Oxycodone is combined with Lithium.
Oxymorphone
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Lithium.
Oxyphenbutazone
The serum concentration of Lithium can be increased when it is combined with Oxyphenbutazone.
p-Hydroxyamphetamine
Lithium may decrease the stimulatory activities of Hydroxyamphetamine.
Paliperidone
Lithium may increase the neurotoxic activities of Paliperidone.
Palonosetron
Palonosetron may increase the serotonergic activities of Lithium.
Pancuronium
Lithium may increase the neuromuscular blocking activities of Pancuronium.
Pancuronium Bromide
Lithium may increase the neuromuscular blocking activities of Pancuronium.
Panobinostat
Lithium may increase the QTc-prolonging activities of Panobinostat.
Paraldehyde
Lithium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Parecoxib
The serum concentration of Lithium can be increased when it is combined with Parecoxib.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Lithium.
Pargyline
The risk or severity of adverse effects can be increased when Pargyline is combined with Lithium.
Paroxetine
Lithium may increase the serotonergic activities of Paroxetine.
Parthenolide
The serum concentration of Lithium can be increased when it is combined with Parthenolide.
Pazopanib
Lithium may increase the QTc-prolonging activities of Pazopanib.
Pentamidine
Lithium may increase the QTc-prolonging activities of Pentamidine.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Lithium.
Pentobarbital
The risk or severity of adverse effects can be increased when Pentobarbital is combined with Lithium.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lithium.
Perazine
Lithium may increase the neurotoxic activities of Perazine.
Perflutren
Lithium may increase the QTc-prolonging activities of Perflutren.
Periciazine
Lithium may increase the neurotoxic activities of Propericiazine.
Perindopril
The serum concentration of Lithium can be increased when it is combined with Perindopril.
Perphenazine
Lithium may increase the neurotoxic activities of Perphenazine.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Lithium.
Phenobarbital
The risk or severity of adverse effects can be increased when Phenobarbital is combined with Lithium.
Phenoxyethanol
The risk or severity of adverse effects can be increased when Lithium is combined with Phenoxyethanol.
Phentermine
Lithium may decrease the stimulatory activities of Phentermine.
PHENTERMINE RESIN
Lithium may decrease the stimulatory activities of Phentermine.
Phenylbutazone
The serum concentration of Lithium can be increased when it is combined with Phenylbutazone.
Phenytoin
The risk or severity of adverse effects can be increased when Phenytoin is combined with Lithium.
Pimecrolimus
The serum concentration of Lithium can be increased when it is combined with Pimecrolimus.
Pimozide
Lithium may increase the neurotoxic activities of Pimozide.
Pipamperone
Lithium may increase the neurotoxic activities of Pipamperone.
Pipecuronium
Lithium may increase the neuromuscular blocking activities of Pipecuronium.
Pipothiazine
Lithium may increase the neurotoxic activities of Pipotiazine.
Piretanide
The serum concentration of Lithium can be decreased when it is combined with Piretanide.
Pirfenidone
The serum concentration of Lithium can be increased when it is combined with Pirfenidone.
Pirinitramide
The risk or severity of adverse effects can be increased when Lithium is combined with Piritramide.
Piroxicam
The serum concentration of Lithium can be increased when it is combined with Piroxicam.
Piroxicam-Beta-Cyclodextrin
The serum concentration of Lithium can be increased when it is combined with Piroxicam.
Pizotyline
The risk or severity of adverse effects can be increased when Pizotifen is combined with Lithium.
Polystyrene Sulfonate
The serum concentration of Lithium can be decreased when it is combined with Tolevamer.
Polystyrene Sulfonic Acid
The serum concentration of Lithium can be decreased when it is combined with Tolevamer.
Polythiazide
Polythiazide may decrease the excretion rate of Lithium which could result in a higher serum level.
Pomalidomide
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Lithium.
Potassium Iodide
Potassium Iodide may increase the hypothyroid activities of Lithium.
Pramipexole
Lithium may increase the sedative activities of Pramipexole.
Pramoxine
The risk or severity of adverse effects can be increased when Lithium is combined with Pramocaine.
Prazepam
The risk or severity of adverse effects can be increased when Lithium is combined with Prazepam.
Pregabalin
The therapeutic efficacy of Lithium can be increased when used in combination with Pregabalin.
Prilocaine
The risk or severity of adverse effects can be increased when Prilocaine is combined with Lithium.
Primaquine
Lithium may increase the QTc-prolonging activities of Primaquine.
Primidone
The risk or severity of adverse effects can be increased when Primidone is combined with Lithium.
Procainamide
Lithium may increase the QTc-prolonging activities of Procainamide.
Procaine
The risk or severity of adverse effects can be increased when Procaine is combined with Lithium.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Lithium.
Prochlorperazine
Lithium may increase the neurotoxic activities of Prochlorperazine.
Promazine
Lithium may increase the neurotoxic activities of Promazine.
Promethazine
The risk or severity of adverse effects can be increased when Promethazine is combined with Lithium.
Propafenone
Lithium may increase the QTc-prolonging activities of Propafenone.
Proparacaine
The risk or severity of adverse effects can be increased when Proparacaine is combined with Lithium.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Lithium.
Propoxyphene
The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lithium.
Prothipendyl
Lithium may increase the neurotoxic activities of Prothipendyl.
Protriptyline
Lithium may increase the neurotoxic activities of Protriptyline.
Pseudoephedrine
Lithium may decrease the stimulatory activities of Pseudoephedrine.
Pyrantel
Lithium may increase the neuromuscular blocking activities of Pyrantel.
Quazepam
The risk or severity of adverse effects can be increased when Quazepam is combined with Lithium.
Quetiapine
Lithium may increase the neurotoxic activities of Quetiapine.
Quetiapine fumarate
Lithium may increase the neurotoxic activities of Quetiapine.
Quinagolide
The therapeutic efficacy of Quinagolide can be decreased when used in combination with Lithium.
Quinapril
The serum concentration of Lithium can be increased when it is combined with Quinapril.
Quinethazone
Quinethazone may decrease the excretion rate of Lithium which could result in a higher serum level.
Quinidine
Lithium may increase the QTc-prolonging activities of Quinidine.
Quinine
Lithium may increase the QTc-prolonging activities of Quinine.
Ramelteon
The risk or severity of adverse effects can be increased when Ramelteon is combined with Lithium.
Ramipril
The serum concentration of Lithium can be increased when it is combined with Ramipril.
Rapacuronium
Lithium may increase the neuromuscular blocking activities of Rapacuronium.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Lithium.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Lithium.
Remoxipride
Lithium may increase the neurotoxic activities of Remoxipride.
Rescinnamine
The serum concentration of Lithium can be increased when it is combined with Rescinnamine.
Reserpine
Lithium may increase the neurotoxic activities of Reserpine.
Resveratrol
The serum concentration of Lithium can be increased when it is combined with Resveratrol.
Risperidone
Lithium may increase the neurotoxic activities of Risperidone.
Rizatriptan
The risk or severity of adverse effects can be increased when Rizatriptan is combined with Lithium.
Rocuronium
Lithium may increase the neuromuscular blocking activities of Rocuronium.
Rofecoxib
The serum concentration of Lithium can be increased when it is combined with Rofecoxib.
Ropinirole
Lithium may increase the sedative activities of Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lithium.
Rotigotine
Lithium may increase the sedative activities of Rotigotine.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Lithium.
Sacubitril
The serum concentration of Lithium can be increased when it is combined with Sacubitril.
Salicylamide
The serum concentration of Lithium can be increased when it is combined with Salicylamide.
Salicylic Acid
The serum concentration of Lithium can be increased when it is combined with Salicylic acid.
Salmon Calcitonin
The serum concentration of Lithium can be decreased when it is combined with Salmon Calcitonin.
Salsalate
The serum concentration of Lithium can be increased when it is combined with Salsalate.
Saquinavir
Lithium may increase the QTc-prolonging activities of Saquinavir.
Saquinavir Mesylate
Lithium may increase the QTc-prolonging activities of Saquinavir.
Saralasin
The serum concentration of Lithium can be increased when it is combined with Saralasin.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Lithium.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Lithium.
Secobarbital
The risk or severity of adverse effects can be increased when Secobarbital is combined with Lithium.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Lithium.
Serratiopeptidase
The serum concentration of Lithium can be increased when it is combined with Serrapeptase.
Sertindole
Lithium may increase the neurotoxic activities of Sertindole.
Sertraline
Lithium may increase the serotonergic activities of Sertraline.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Lithium.
Sodium Bicarbonate
Sodium bicarbonate may increase the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
Sodium Chloride
Sodium Chloride may increase the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
Sodium Oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lithium.
Sotalol
Lithium may increase the QTc-prolonging activities of Sotalol.
Spirapril
The serum concentration of Lithium can be increased when it is combined with Spirapril.
Succinylcholine
Lithium may increase the neuromuscular blocking activities of Succinylcholine.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Lithium.
Sulfasalazine
The serum concentration of Lithium can be increased when it is combined with Sulfasalazine.
Sulfisoxazole
Lithium may increase the QTc-prolonging activities of Sulfisoxazole.
Sulindac
The serum concentration of Lithium can be increased when it is combined with Sulindac.
Sulpiride
Lithium may increase the antipsychotic activities of Sulpiride.
Sumatriptan
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Lithium.
Sumatriptan Succinate
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Lithium.
Suprofen
The serum concentration of Lithium can be increased when it is combined with Suprofen.
Suvorexant
Lithium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lithium.
Tasimelteon
The risk or severity of adverse effects can be increased when Tasimelteon is combined with Lithium.
Tedizolid
Tedizolid Phosphate may increase the serotonergic activities of Lithium.
Tedizolid Phosphate
Tedizolid Phosphate may increase the serotonergic activities of Lithium.
Telavancin
Lithium may increase the QTc-prolonging activities of Telavancin.
Telithromycin
Lithium may increase the QTc-prolonging activities of Telithromycin.
Telmisartan
The serum concentration of Lithium can be increased when it is combined with Telmisartan.
Temazepam
The risk or severity of adverse effects can be increased when Temazepam is combined with Lithium.
Tenoxicam
The serum concentration of Lithium can be increased when it is combined with Tenoxicam.
Teriflunomide
The serum concentration of Lithium can be increased when it is combined with Teriflunomide.
Tetrabenazine
The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lithium.
Tetracaine
The risk or severity of adverse effects can be increased when Lithium is combined with Tetracaine.
Tetracaine hydrochloride
The risk or severity of adverse effects can be increased when Lithium is combined with Tetracaine.
Tetrahydrocannabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Lithium.
Thalidomide
Lithium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Theophylline
The serum concentration of Lithium can be decreased when it is combined with Theophylline.
Theophylline anhydrous
The serum concentration of Lithium can be decreased when it is combined with Theophylline.
Thiamylal
The risk or severity of adverse effects can be increased when Thiamylal is combined with Lithium.
Thiopental
The risk or severity of adverse effects can be increased when Thiopental is combined with Lithium.
Thiopental Sodium
The risk or severity of adverse effects can be increased when Thiopental is combined with Lithium.
Thioproperazine
Lithium may increase the neurotoxic activities of Thioproperazine.
Thioridazine
Lithium may increase the neurotoxic activities of Thioridazine.
Thiothixene
Lithium may increase the neurotoxic activities of Thiothixene.
Tiagabine
The risk or severity of adverse effects can be increased when Tiagabine is combined with Lithium.
Tianeptine
Lithium may increase the neurotoxic activities of Tianeptine.
Tiapride
Lithium may increase the neurotoxic activities of Tiapride.
Tiaprofenic Acid
The serum concentration of Lithium can be increased when it is combined with Tiaprofenic acid.
Tizanidine
The risk or severity of adverse effects can be increased when Tizanidine is combined with Lithium.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Lithium.
Tolfenamic Acid
The serum concentration of Lithium can be increased when it is combined with Tolfenamic Acid.
Tolmetin
The serum concentration of Lithium can be increased when it is combined with Tolmetin.
Toloxatone
The risk or severity of adverse effects can be increased when Toloxatone is combined with Lithium.
Topiramate
The serum concentration of Lithium can be increased when it is combined with Topiramate.
Toremifene
Lithium may increase the QTc-prolonging activities of Toremifene.
Torsemide
The serum concentration of Lithium can be decreased when it is combined with Torasemide.
Tramadol
The risk or severity of adverse effects can be increased when Tramadol is combined with Lithium.
Trandolapril
The serum concentration of Lithium can be increased when it is combined with Trandolapril.
Tranilast
The serum concentration of Lithium can be increased when it is combined with Tranilast.
Tranylcypromine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lithium.
Trazodone
The risk or severity of adverse effects can be increased when Trazodone is combined with Lithium.
Triazolam
The risk or severity of adverse effects can be increased when Triazolam is combined with Lithium.
Triazulenone
The risk or severity of adverse effects can be increased when Lithium is combined with Loprazolam.
Trichlormethiazide
Trichlormethiazide may decrease the excretion rate of Lithium which could result in a higher serum level.
Trifluoperazine
Lithium may increase the neurotoxic activities of Trifluoperazine.
Triflupromazine
Lithium may increase the neurotoxic activities of Triflupromazine.
Trimipramine
Lithium may increase the neurotoxic activities of Trimipramine.
Triprolidine
The risk or severity of adverse effects can be increased when Triprolidine is combined with Lithium.
Tropisetron
Tropisetron may increase the serotonergic activities of Lithium.
Tryptophan
L-Tryptophan may increase the serotonergic activities of Lithium.
Tubocurarine
Lithium may increase the neuromuscular blocking activities of Tubocurarine.
Urethane
The risk or severity of adverse effects can be increased when Lithium is combined with Ethyl carbamate.
Valdecoxib
The serum concentration of Lithium can be increased when it is combined with Valdecoxib.
Valproate
The risk or severity of adverse effects can be increased when Valproic Acid is combined with Lithium.
Valproic Acid
The risk or severity of adverse effects can be increased when Valproic Acid is combined with Lithium.
Valsartan
The serum concentration of Lithium can be increased when it is combined with Valsartan.
Vandetanib
Lithium may increase the QTc-prolonging activities of Vandetanib.
Vecuronium
Lithium may increase the neuromuscular blocking activities of Vecuronium.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lithium.
Venlafaxine
Lithium may increase the serotonergic activities of Venlafaxine.
Verapamil
Verapamil may increase the neurotoxic activities of Lithium.
Vigabatrin
The risk or severity of adverse effects can be increased when Vigabatrin is combined with Lithium.
Vilazodone
The risk or severity of adverse effects can be increased when Vilazodone is combined with Lithium.
Vortioxetine
The risk or severity of adverse effects can be increased when Vortioxetine is combined with Lithium.
Zaleplon
The risk or severity of adverse effects can be increased when Zaleplon is combined with Lithium.
Ziconotide
The risk or severity of adverse effects can be increased when Ziconotide is combined with Lithium.
Zileuton
The serum concentration of Lithium can be increased when it is combined with Zileuton.
Ziprasidone
Lithium may increase the neurotoxic activities of Ziprasidone.
Zofenopril
The serum concentration of Lithium can be increased when it is combined with Zofenopril.
Zolmitriptan
The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lithium.
Zolpidem
Lithium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zomepirac
The serum concentration of Lithium can be increased when it is combined with Zomepirac.
Zonisamide
The risk or severity of adverse effects can be increased when Zonisamide is combined with Lithium.
Zopiclone
The risk or severity of adverse effects can be increased when Zopiclone is combined with Lithium.
Zotepine
Lithium may increase the neurotoxic activities of Zotepine.
Zuclopenthixol
Lithium may increase the neurotoxic activities of Zuclopenthixol.
